A Phase I, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AT03-65 in Adults with Advanced Solid Tumors

Sponsor:

Axcynsis Therapeutics Pte, Ltd

Sponsor Study ID:

AT0365-P1-01

CTO #:

104199

NCT Number:

NCT06809114

Phase:

Early Phase I

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Lung; Ovary

Study Objectives:

To evaluate the safety and tolerability of AT03-65 in subjects with advanced/ metastatic solid tumors. To explore the MTD by observing dose limiting toxicity of AT03-65 and/or to provide support for the determination of the RP2D.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)